As opioid-related deaths skyrocket across the U.S., momentum to combat the epidemic has been mounting in Washington. But the crisis has also highlighted a glaring problem that no amount of politics or policymaking will solve soon: The lack of non-addictive pain... Read more »
[Corrected, 11/1/17, 5:20 p.m. ET. See below.] The annual American Society of Hematology meeting is next month. But previews of the big data presentations are out today, yielding more insight into what promises to be the first major... Read more »
As top lawyers from Facebook, Google, and Twitter testify on Capitol Hill this week about Russians using their platforms to interfere in the 2016 U.S. presidential election, it’s becoming clearer that the fight against the spread of fake news won’t be... Read more »
News is constantly streaming out these days about the role of Facebook, Twitter, and Google in the 2016 presidential election; most disturbing to the public is the apparent use of social media, search, and video channels by Russian operatives seeking to... Read more »
The White House and the FDA turned the spotlight on the nation’s opioid crisis. Blockbuster drugs from Alexion and Tesaro gained expanded approvals, but bad earnings news from Celgene and Biogen brought stocks down. Academics in the U.S. and China made... Read more »
As the quest to find treatments for Alzheimer’s disease keeps crashing against rocks, a group of researchers in the field want their peers to pay more attention to the part of the brain where Alzheimer’s disease first wreaks havoc.
A new... Read more »
Hey folks. If you’re thinking about breaking away from the cable monopolies and getting your data, music, and video in other ways, congratulations, I’m with you. I cut the cord back in 2009, and now millions of people are doing the... Read more »
Kite Pharma wasn’t expecting a regulatory decision for its non-Hodgkin lymphoma treatment until November, but this week, the company got the FDA’s O.K.
The approval of axicabtagene ciloleucel (Yescarta) marks the second time in the two months that the FDA has... Read more »
The conventional wisdom about Silicon Valley is that it’s a playground for the underdogs, a fertile ground for young entrepreneurs building startups that are going to “change the world.”
Instead, the Bay Area—while, yes, still home to thirsty young entrepreneurs—is increasingly... Read more »